Precision BioSciences, Inc. (NASDAQ:DTIL) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) have received a consensus recommendation of “Moderate Buy” from the five brokerages that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $32.25.

A number of brokerages recently commented on DTIL. JonesTrading restated a “buy” rating and set a $30.00 target price on shares of Precision BioSciences in a report on Friday, April 17th. HC Wainwright reissued a “buy” rating on shares of Precision BioSciences in a research report on Thursday, July 9th. Oppenheimer assumed coverage on shares of Precision BioSciences in a report on Tuesday, June 9th. They issued an “outperform” rating and a $20.00 price objective for the company. Finally, Weiss Ratings upgraded shares of Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 8th.

Precision BioSciences Trading Down 1.1%

DTIL opened at $7.17 on Wednesday. Precision BioSciences has a one year low of $3.53 and a one year high of $9.62. The company has a debt-to-equity ratio of 0.29, a current ratio of 14.02 and a quick ratio of 14.02. The business has a 50 day simple moving average of $7.36 and a two-hundred day simple moving average of $6.17. The firm has a market capitalization of $184.99 million, a price-to-earnings ratio of -1.95 and a beta of 1.25.

Precision BioSciences (NASDAQ:DTIL) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.09). Precision BioSciences had a negative return on equity of 85.37% and a negative net margin of 96.73%.The business had revenue of $10.84 million during the quarter, compared to the consensus estimate of $4.05 million. Analysts predict that Precision BioSciences will post -2.21 EPS for the current year.

Hedge Funds Weigh In On Precision BioSciences

A number of institutional investors have recently bought and sold shares of DTIL. HBK Sorce Advisory LLC purchased a new stake in Precision BioSciences in the fourth quarter worth about $38,000. Engineers Gate Manager LP bought a new stake in Precision BioSciences during the 4th quarter valued at approximately $43,000. Occudo Quantitative Strategies LP purchased a new position in shares of Precision BioSciences during the 4th quarter worth approximately $52,000. Miller Financial Services LLC grew its holdings in shares of Precision BioSciences by 50.0% during the 4th quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock worth $62,000 after acquiring an additional 5,000 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of Precision BioSciences in the 3rd quarter worth approximately $84,000. 37.99% of the stock is owned by institutional investors.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.